Article Regarding Citizen Petitions by Goodwin’s Scott Lassman

Goodwin

We post frequently about citizen petitions here on the blog.  Since the 1970s, the citizen petition process has allowed individual persons or organizations to request that FDA take or not take certain regulatory actions, such as not approving pending new drug applications.  In recent years, the citizen petition process has come under fire as critics have claimed that pharmaceutical companies use (and abuse) the process to delay market entry of potential competitor products.  Yesterday, Law360 published an article by Goodwin attorney and Big Molecule Watch editor Scott Lassman commenting on the merit, or lack thereof, of these criticisms.

Download PDF

Comments are closed.